BioSpace News Archive

Prime Medicine, Inc. reported financial results for the first quarter ended March 31, 2024, and provided a business update.

Curis, Inc. announced that the Company will present updated data from the TakeAim Leukemia study Tuesday, May 14, 2024, at 4:00 p.m. ET.

CorMedix Inc. today announced that management will be participating in fireside chats and investor meetings at both the JMP Securities Life Sciences Conference being held in New York on May 13 – 14, 2024 and the 2024 RBC Capital Markets Global Healthcare Conference being held in New York.

iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported financial results for the first quarter ended March 31, 2024 and provided a business update.

Citius Pharmaceuticals, Inc. today announced its participation in two upcoming investor conferences.

Xenetic Biosciences, Inc. today reported its financial results for the first quarter of 2024 and provided a business update.

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended March 31, 2024, on Wednesday, May 15, 2024, after the market closes.

The Jackson Laboratory, an independent, nonprofit biomedical research organization, and AbTherx, an innovator in biotechnology, announced a strategic partnership to develop and commercialize cutting-edge tools to expedite antibody discovery and derisk the development of vital new therapies.

Inhibrx, Inc. announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary Inhibrx Biosciences, Inc. to holders of shares of the Company’s common stock on a pro rata basis.

Evolus, Inc., a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, reported the grant of non-qualified stock options to purchase an aggregate of 10,990 shares of Evolus and an aggregate of 42,759 restricted stock units of the company’s common stock to 14 newly hired non-executive employees of the company.